
Please try another search
Pfizer Inc. (NYSE:PFE), a global biopharmaceutical giant with a market capitalization of $143 billion, finds itself at a critical juncture as it navigates a shifting landscape of clinical trial...
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. reported positive results from a Phase 3 clinical trial evaluating their combination therapy for muscle-invasive bladder cancer patients who cannot...
NEW HAVEN - The U.S. Food and Drug Administration has accepted the New Drug Application for vepdegestrant, an investigational treatment for patients with estrogen receptor-positive, HER2-negative,...
Investing.com - Morgan Stanley (NYSE:MS) has raised its price target on Pfizer (NYSE:PFE) stock to $33.00 from $32.00 while maintaining an Equalweight rating on the pharmaceutical giant....
Investing.com -- The S&P 500 closed lower Tuesday after data showing services activity unexpectedly contracted stoked concerns about the underlying of the economy just as the quarterly earnings season...
Introduction & Market Context Pfizer Inc. (NYSE:PFE) presented its second quarter 2025 earnings results on August 5, showcasing strong financial performance that exceeded analyst expectations. The...
Pfizer Inc. reported stronger-than-expected earnings for the second quarter of 2025, with both revenue and earnings per share (EPS) surpassing analyst forecasts. The pharmaceutical giant posted an EPS...
Investing.com -- U.S. stocks fell sharply on Friday as markets opened August with renewed concerns about economic weakness and the impact of newly adjusted tariffs announced by President Donald...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review